References
- Juliusson G., Liliemark J. High complete remission rate from 2-chloro 2′deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count. J. Clin. Oncol. 1993; 11: 570–574
- O'Brien S. Infections during purine analogue therapy. Hematol. Cell The 1997; 39: 43, abstr.)
- Juliusson G. Complications in the treatment of CLL with purine analogues. Hematol. Cell. The 1997; 39: 541–542
- Knauf W. U., Hingenfeld E., SchÜTte H. J., Schrtte H. J., SchrÖDer J., Kath R., Thiel E. 2 CdA in the treatment of CLL: high effectiveness, but remarkable rate of infection. Hematol. Cell. Ther 1997; 39: 588, (abstr.)
- Kumar A., Farace E, Gaudin C., Triebel F. Clonal T cell expansion induced by interleukin-2 therapy in blood and tumors. J. Clin. Invest. 1996; 97: 1219–1226
- Peest D., Leo R., Bloche S., Hein B., Stannat-Kiessling S., Tschechne B., Fett W., Harms P., Hoffmann L., Bartl R., Wacker H. H., Gorg S., Atzpodien J., Lrchner H., Deicher H. Low-dose recombinant IL-2 therapy in advanced multiple myeloma. Brit. J. Haemat. 1995; 89: 328–337
- Rob & T., BasiŃSka-Morawiec M., Krykowski E., Kasznicki M., PluzaŃKa A., Potomski P., Hellmann A., Zaucha J. M., Lewandowski K., DmoszyŃSka A., Hansz J., Komarnicki M., Konopka L., DurzyŃSki T., Ceglarek B., Sikorska A., Kot-Larek-Haus S., Mazurek G., UrasiŃSki J., Zdziarska B., Maj S., KopeĆ J., Skotnicki A. B., Dwilewicz-Trojaczek J., Kura-Towska Z., Grieb P. Intermittent 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemia. Leuk. Lymph. 1195; 18: 179–184
- Dmoszyńska A., Kandefer-SzerszeĆ M., LegieĆ W., RoliŃSki J., KamiŃSka X. Cytokine production, Il-2 surface and soluble receptors during Il-2 treatment. Brit J. Haemat. 1998; 102: 82, abstr).
- Seymour J. F., Estey E. H., Keating M. J., Kurzrock R. Response to interferon α in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine. Leukemia 1995; 9: 929–932
- Von Rohr A., Betticher M. F., Fey M. F., Racine C., Tobler A., Cerny X. Treatment with combined 2-chlorodeoxyadenosine and interleukin-2 for low grade malignancies: pilot studies. Proceedings of ASCO 1997; 17: 18a
- Dmoszyńska A., LegieĆ W., Kandefer-SzerszeĆ M., RoliŃSki J., Kamińska X. Decreased production of tumor necrosis factor (TNFα) by patients lymphocytes during treatment with very low doses of interleukin-2. Acta Haematol. Pol. 1998; 29: 45–51
- Kandefer-szerszeń M., LegieĆ W., DmoszyŃSka A., Szuster-ciesielska A. Modulating effect of IL-2 therapy on interferon production by blood leukocytes of patients with minimal residual disease. Arch. Immunol. Ther Exp. 1998; 45: 177–181
- Roliński J., Legie W., Dmoszyńska A. Influence of low dose subcutaneous interleukin 2 therapy on NK cell population in patients with hematological malignancies. Annales Univ. M. Curie-Skbdowska, Lublin, Poland 1996; 51: 143–148
- Hänninen E. L., KÖRfer A., Hadam M., Schneekloth C., Dall-Mann I., Menzel T., Kirchner H., Poliwoda H., Atzpodien J. Biological monitoring of low-dose interleukin 2 in humans: soluble interleulun 2 receptors, cytokines, and cell surface phenotypes. Cancer Research 1991; 50: 63312–6316
- De Paoli P., Zanussi S., Simonelli C., Bortolin M. T., D'Andrea M., Crepaldi C., Talamini R., Comar M., Giacca M., Tirelli U. Effects of subcutaneous IL-2 therapy on CD4 subsets and in vitro cytokine production in HIV subjects. J. Clin. Invest. 1997; 100: 2737–2143
- Ghezzi S., Vicenzi Soldini L., Tambussi G., Muronea M., Lazzarin A., Poli G. Experiences in immune reconstruction. The rationale for IL-2 administration to HIV-infected individuals. J. Biol. Regul. Homeost. Agent 1997; 11: 74–78
- Hausler M., Meilicke R., Franke E., Schweizer K., Kusenbach G. Interleukin 2 increases helper-cell counts in common variable immunodeficiency in vivo. Brit. J. Haemat. 1998; 102: 88, (abstr.).
- Fenchel K., Hoffmann J., Borghardt H., Kircher H., Pralle A., Ganser A., Atzpodien J. Interleukin 2 reduces the CD 4′ cell depletion following fludarabine and idarubicin combination therapy. Brit. J. Haemat. 1998; 102: 89, (abstr.).